66 related articles for article (PubMed ID: 30726563)
1. Risk factors of rescue bismuth quadruple therapy failure for Helicobacter pylori eradication.
Lee JW; Kim N; Nam RH; Lee SM; Soo In C; Kim JM; Lee DH
J Gastroenterol Hepatol; 2019 Apr; 34(4):666-672. PubMed ID: 30726563
[TBL] [Abstract][Full Text] [Related]
2. Two Different 1-Week Quadruple Therapies Given Back-to-Back Consecutive Therapy for Difficult-to-Treat Helicobacter pylori Infection: A Pilot Study.
Liu J; Ji CR; Li YY; Qiao C; Hu JN; Wan M; Lin MJ; Lin BS; Wang J; Zha J; Li LX; Zuo XL
Clin Transl Gastroenterol; 2021 Aug; 12(8):e00391. PubMed ID: 34397042
[TBL] [Abstract][Full Text] [Related]
3. Second-line bismuth-containing quadruple therapy for
Kim SE; Park MI; Park SJ; Moon W; Kim JH; Jung K; Kim HK; Lee YD
World J Gastroenterol; 2017 Feb; 23(6):1059-1066. PubMed ID: 28246480
[TBL] [Abstract][Full Text] [Related]
4. Antibiotic susceptibility, heteroresistance, and updated treatment strategies in
Mascellino MT; Porowska B; De Angelis M; Oliva A
Drug Des Devel Ther; 2017; 11():2209-2220. PubMed ID: 28814829
[TBL] [Abstract][Full Text] [Related]
5. Description of a Case of
Merle S; Bland S; Bénéjat L; Ducournau A; Jehanne Q; Bessède E; Jauvain M; Heluwaert F; Lehours P
Microb Drug Resist; 2024 Apr; 30(4):164-167. PubMed ID: 38060816
[TBL] [Abstract][Full Text] [Related]
6. Eradication of Helicobacter pylori Infection.
Marcus EA; Sachs G; Scott DR
Curr Gastroenterol Rep; 2016 Jul; 18(7):33. PubMed ID: 27177639
[TBL] [Abstract][Full Text] [Related]
7. Nitazoxanide, a potential drug for eradication of Helicobacter pylori with no cross-resistance to metronidazole.
Mégraud F; Occhialini A; Rossignol JF
Antimicrob Agents Chemother; 1998 Nov; 42(11):2836-40. PubMed ID: 9797212
[TBL] [Abstract][Full Text] [Related]
8. Alcohol increases treatment failure for Helicobacter pylori eradication in Asian populations.
Yu J; Lv Y; Yang P; Jiang Y; Qin X; Wang X
BMC Gastroenterol; 2023 Oct; 23(1):365. PubMed ID: 37880587
[TBL] [Abstract][Full Text] [Related]
9. Current paradigms in the management of refractory Helicobacter pylori infection.
Jearth V; Panigrahi MK
Indian J Gastroenterol; 2023 Dec; 42(6):766-779. PubMed ID: 37737326
[TBL] [Abstract][Full Text] [Related]
10. The efficacy and safety of vonoprazan in quadruple therapy for
Zhuang X; Jiang H; Jin D; Sun M; Wang Z; Wang X
Gastroenterol Rep (Oxf); 2024; 12():goae036. PubMed ID: 38628396
[TBL] [Abstract][Full Text] [Related]
11. Factors Affect the Eradication Rate of
Lan QL; Sun HY; Ye Y; Wang Y; Liu Y; Weng XJ
Infect Drug Resist; 2022; 15():2339-2345. PubMed ID: 35517896
[TBL] [Abstract][Full Text] [Related]
12. Alanine racemase a promising Helicobacter pylori drug target inhibited by propanoic acid.
Ibrahim KA; El-Ashrey MK; Kashef MT; Helmy OM
Microbes Infect; 2023; 25(7):105167. PubMed ID: 37271368
[TBL] [Abstract][Full Text] [Related]
13. Assessing the side effects and resistance in H. pylori treatment: a discussion on minocycline versus tetracycline therapy.
Kurokawa T; Kurokawa T
J Gastroenterol; 2024 Apr; 59(4):357. PubMed ID: 38416245
[No Abstract] [Full Text] [Related]
14. Bismuth Subcitrate, Metronidazole and Tetracycline - A Rare Cause of Drug-Induced Liver Injury.
Silva C; Merim S; Sevivas R; Mota J; Leitão A
Eur J Case Rep Intern Med; 2023; 10(12):004119. PubMed ID: 38077712
[TBL] [Abstract][Full Text] [Related]
15. Determination of metronidazole in a rat stomach by HPLC for obtaining basic data of the eradication therapy of
Kubodera M; Tokumura T; Machida Y
J Pharm Anal; 2012 Oct; 2(5):378-381. PubMed ID: 29403770
[TBL] [Abstract][Full Text] [Related]
16. Second-line levofloxacin-based quadruple therapy versus bismuth-based quadruple therapy for Helicobacter pylori eradication and long-term changes to the gut microbiota and antibiotic resistome: a multicentre, open-label, randomised controlled trial.
Liou JM; Jiang XT; Chen CC; Luo JC; Bair MJ; Chen PY; Chou CK; Fang YJ; Chen MJ; Chen CC; Lee JY; Yang TH; Yu CC; Kuo CC; Chiu MC; Chen CY; Shun CT; Hu WH; Tsai MH; Hsu YC; Tseng CH; Chang CY; Lin JT; El-Omar EM; Wu MS;
Lancet Gastroenterol Hepatol; 2023 Mar; 8(3):228-241. PubMed ID: 36549320
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of high-dose esomeprazole-amoxicillin dual therapy for Helicobacter pylori rescue treatment: a multicenter, prospective, randomized, controlled trial.
Bi H; Chen X; Chen Y; Zhao X; Wang S; Wang J; Lyu T; Han S; Lin T; Li M; Yuan D; Liu J; Shi Y
Chin Med J (Engl); 2022 Jul; 135(14):1707-1715. PubMed ID: 36193978
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of bismuth quadruple regimens containing tetracycline or furazolidone for initial eradication of Helicobacter pylori.
Wang J; Cao Y; He W; Li X
Medicine (Baltimore); 2021 Dec; 100(51):e28323. PubMed ID: 34941132
[TBL] [Abstract][Full Text] [Related]
19. Levofloxacin+Tetracycline Quadruple Regimen for Eradication of
Alavinejad P; Nayebi M; Parsi A; Abdelsameea E; Ahmed MH; Hormati A; Viet Hang D; Pezeshgi Modarres M; Cheraghian B; Baghaee S; Farbod Ara T; Trung Tran Q; Shanker Behl N; Hashemi SJ; Alboraie M; Salman S; Nha L; V Patai Á; Hajiani E; Abravesh AA
Middle East J Dig Dis; 2023 Jan; 15(1):12-18. PubMed ID: 37547163
[No Abstract] [Full Text] [Related]
20. Epidemiology of
Mladenova I
Antibiotics (Basel); 2023 Jul; 12(7):. PubMed ID: 37508280
[No Abstract] [Full Text] [Related]
[Next] [New Search]
